Notably, although we demonstrated that Th17 cells are a dominant population in CD4+ TILs in both breast cancer models, we did not find any correlations between numbers of tumor-infiltrating IL-17+ cells with clinicopathological parameters in breast cancer patients. The gene discussed is IL17A; the disease is neoplasm.